| Q35234354 | Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma |
| Q58748654 | Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma |
| Q72871412 | Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma |
| Q37069223 | Established and Emerging Biomarkers in Cutaneous Malignant Melanoma |
| Q44673456 | Evaluation of new putative tumor markers for melanoma |
| Q36549523 | Immunohistochemistry and electron microscopy in Langerhans cell histiocytosis confined to the skin |
| Q77366782 | Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma |
| Q46364109 | Pigmented nail with atypical melanocytic hyperplasia |
| Q73003073 | Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression |
| Q40789228 | Staging of melanoma |
| Q36293004 | The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma |